Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
Prostate cancer (PC) is the most common malignancy and the fifth cause of cancer death in men. The treatment for localized or locally advanced stages offers a high probability of cure. Even though the therapeutic landscape has significantly improved over the last decade, metastatic PC (mPC) still ha...
Main Authors: | Clara Martori, Lidia Sanchez-Moral, Tony Paul, Juan Carlos Pardo, Albert Font, Vicenç Ruiz de Porras, Maria-Rosa Sarrias |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/2/440 |
Similar Items
-
Nanotechnology-enhanced immunotherapy for metastatic cancer
by: Peisen Zhang, et al.
Published: (2021-11-01) -
Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
by: Amy J. Petty, et al.
Published: (2021-10-01) -
Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies
by: Tao Shi, et al.
Published: (2023-06-01) -
Editorial: Overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine
by: Aimin Jiang, et al.
Published: (2024-04-01) -
Cancer immunotherapies: advances and bottlenecks
by: Rui Rui, et al.
Published: (2023-08-01)